Intercept Pharmaceuticals's General Counsel and Secretary just picked up 44,277 shares

Jared Freedberg, Intercept Pharmaceuticals's General Counsel and Secretary, recently acquired 44,277 shares of the company. The buys took place at $0.00 per share (and therefore, likely the result of option or restricted share grants), on February 01, 2021. Freedberg now owns 44,277 shares of the company. Freedberg operates out of New York, NY. Some additional info was provided as follows:


Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The award shall be subject to a four-year vesting period, with 25% of the shares subject to the award vesting in an initial annual installment following the Vesting Commencement Date and the remaining share s vesting pro rata on each subsequent three-month anniversary of the Vesting Commencement Date. The Vesting Commencement Date is February 1, 2021.
The award shall be subject to a four-year vesting period, with 25% of the shares subject to the award vesting and becoming exercisable in an initial annual installment following the Vesting Commencement Date and 1/48th of the shares subject to the award vesting and becoming exercisable each month thereafter. The Vesting Commencement Date is February 1, 2021.

The above information was disclosed in a filing to the SEC. To see the filing, click here.

To receive a free e-mail notification whenever Intercept Pharmaceuticals makes a similar move, sign up!

Other recent filings from the company include the following:

Intercept Pharmaceuticals's Chief Qual. Officer & SVP Ops. just disposed of 2,455 shares - Jan. 13, 2022
Departure of Directors or Certain - Jan. 10, 2022
Statement of changes in beneficial ownership of securities - Jan. 4, 2022
SVP of Intercept Pharmaceuticals just disposed of 2,455 shares - Jan. 4, 2022
SVP of Intercept Pharmaceuticals just disposed of 542 shares - Jan. 4, 2022

Auto Refresh

Feedback